Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Tarsus Pharmaceuticals (TARS) Receivables - Other (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Receivables - Other data on record, last reported at $2.1 million in Q4 2025.

  • For Q4 2025, Receivables - Other rose 57.97% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, up 57.97%, while the annual FY2025 figure was $2.1 million, 57.97% up from the prior year.
  • Receivables - Other reached $2.1 million in Q4 2025 per TARS's latest filing, up from $1.7 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $7.2 million in Q1 2021 and bottomed at $139000.0 in Q3 2021.
  • Average Receivables - Other over 5 years is $1.4 million, with a median of $1.1 million recorded in 2023.
  • Peak YoY movement for Receivables - Other: soared 13800.0% in 2021, then tumbled 95.75% in 2022.
  • A 5-year view of Receivables - Other shows it stood at $200000.0 in 2021, then soared by 1691.0% to $3.6 million in 2022, then crashed by 69.49% to $1.1 million in 2023, then grew by 18.85% to $1.3 million in 2024, then surged by 57.97% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $2.1 million in Q4 2025, $1.7 million in Q3 2025, and $1.9 million in Q2 2025.